Where no man has gone before: the technologies being used to explore MM epigenetic factors
In recent years, researchers have become increasingly aware of the fact that epigenetic alterations can contribute to the formation of multiple myeloma (MM); however, our understanding of these remain... Author: VJHemOnc Added: 12/06/2017
We describe the clinicopathologic features of 17 patients who had a hematologic malignancy of various types, were treated, and subsequently developed a lymphoproliferative disorder (LPD). There were 10 men and 7 women with a median age of 59 years (range, 36 to 83 y). The primary hematologic neoplasms included: 5 chronic lymphocytic leukemia/small lymphocytic lymphoma, 3 plasma cell myeloma, 2 acute monoblastic leukemia, and 1 case each of mixed-phenotype acute leukemia, chronic myeloid leukemia, splenic marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, T-cell prolymphocytic leukemia, and peripheral...
Conditions: Lymphoma; Myeloma; Leukemia; Aplastic Anemia Interventions: Other: Inspiratory Muscle Training; Other: Aerobic Training Sponsor: Daniel Godoy Martinez Recruiting
Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo, Published online: 14 December 2017; doi:10.1038/bjc.2017.432Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo
Conditions: Lymphoma; Solid Malignancy; Alzheimer Disease; Myeloma Interventions: Drug: PU-AD; Device: PET Scan; Other: Blood Draws Sponsors: Samus Therapeutics, Inc.; Memorial Sloan Kettering Cancer Center; Weill Medical College of Cornell University; Rockefeller University Recruiting
The first phase 3 trial in patients with newly diagnosed multiple myeloma found that daratumumab significantly improved progression-free survival when combined with triple therapy.Medscape Medical News
In this activity, Congress Chair Dr. Morton Coleman and CLL Session Co-Chair Dr. Richard R. Furman discuss highlights of the second day of Lymphoma & Myeloma 2017: An International Congress on Hem... Author: imedex Added: 12/13/2017
In this Key Insights activity, Congress Chair Dr. Morton Coleman and Lymphoma Session Co-Chair Dr. John Leonard discuss highlights of the third day of Lymphoma &Myeloma 2017: An International Congre... Author: imedex Added: 12/13/2017
I had blood tests (and the Bence Jones 24-hour urine test) last week. This afternoon I got my results. Here goes, in a nutshell: My M-spike has gone down (it has actually been going down a wee bit for the past two tests, so this is the third “wee bit down”). Total IgG is also down (for the second time, when compared to my last few tests). My hemoglobin is in the normal range, even though my red blood cells are slightly low, but just slightly. Everything else looks pretty much the same. Almost everything, certainly anything of importance, is a wee bit better compared to my most recent tests. For example, my mon...
In this Key Insights activity, Drs. Morton Coleman and Ruben Niesvizky discuss highlights of the first day of Lymphoma &Myeloma 2017: An International Congress on Hematologic Malignancies held in Oc... Author: imedex Added: 12/13/2017
Conclusion The recommended dose of NK012 monotherapy for RRMM patients was concluded to be 20 mg/m2. However, this phase I/II study was terminated at the end of the phase I stage because no patients showed an objective response. Additional clinical studies of combination therapy with NK012 and other agents are warranted. PMID: 29225263 [PubMed - as supplied by publisher]